Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.chroma.2025.465671 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Decision Rules for Termination of Resuscitation-A Roadmap for Challenging Terrain.
JAMA Intern Med
January 2025
Associate Editor, JAMA Internal Medicine.
Effect of Ozoralizumab Administration with or without Methotrexate in Patients with Rheumatoid Arthritis: A Post-Hoc Analysis.
Rheumatol Ther
January 2025
Saitama Medical University, 38 Morohongo, Moroyama-machi, Iruma-gun, Saitama, 350-0495, Japan.
Introduction: Ozoralizumab (OZR) is a novel tumor necrosis factor (TNF) inhibitor that was launched in Japan for treating patients with rheumatoid arthritis (RA) who have had an inadequate response to existing therapies. This post-hoc analysis aimed to compare the efficacy of OZR administered without methotrexate (MTX) with placebo or OZR administration in combination with MTX.
Methods: We analyzed the OZR group (30 mg) in the NATSUZORA trial (non-MTX, open trial) (OZR group; n = 94) and the placebo group (MTX group; n = 75) and the 30-mg OZR group (OZR + MTX group; n = 152) in the OHZORA trial (combined MTX, double-blind trial), and the covariates were adjusted by propensity score matching.
Using toxidromes in the ICU.
Intensive Care Med
January 2025
Department of Emergency Medicine, SUNY Downstate Health Sciences University, Brooklyn, NY, USA.
EAACI Clinical and Research Fellowship Program: Shaping the Future of Allergy and Clinical Immunology.
Allergy
January 2025
Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid, Spain.
The neonatal gut microbiome in health and disease.
Gut Microbes
December 2025
Division of Gastroenterology, Hepatology & Nutrition, Department of Pediatrics, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!